Sequestration of chaperones and proteasome into Lafora bodies and proteasomal dysfunction induced by Lafora disease-associated mutations of malin

Human Molecular Genetics

Volumn 19, Issue 23, 2010, Pages 4726-4734

  Rao, Sudheendra N R ^a   Maity, Ranjan ^a   Sharma, Jaiprakash ^a   Dey, Parthanarayan ^a   Shankar, Susarla Krishna ^b   Satishchandra, Parthasarathy ^b   Jana, Nihar Ranjan ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

^b NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CHAPERONE; HEAT SHOCK COGNATE PROTEIN 70; HEAT SHOCK PROTEIN 70; LAFORIN; MALIN; MUTANT PROTEIN; PHOSPHOPROTEIN PHOSPHATASE; PROTEASOME; UBIQUITIN; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; GENE MUTATION; HUMAN; HUMAN TISSUE; MYOCLONUS EPILEPSY; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SKIN BIOPSY;

ANIMALS; CARRIER PROTEINS; CELL DEATH; CERCOPITHECUS AETHIOPS; COS CELLS; FLUORESCENT ANTIBODY TECHNIQUE; GLUCANS; HSC70 HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; INCLUSION BODIES; LAFORA DISEASE; MOLECULAR CHAPERONES; MUTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; UBIQUITIN;

EID: 78149272475     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddq407     Document Type: Article

References (48)

1. Singh, S. and Ganesh, S. (2009) Lafora progressive myoclonus epilepsy: a meta-analysis of reported mutations in the first decade following the discovery of the EPM2A and NHLRC1 genes. Hum. Mutat., 30, 715-723.
2. Minassian, B.A. (2001) Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr. Neurol., 25, 21-29.
3. Acharya, J.N., Satischandra, P., Asha, T. and Shankar, S.K. (1993) Lafora's disease in south India: a clinical, electrophysiologic, and pathologic study. Epilepsia, 34, 476-87.
4. Delgado-Escueta, A.V. (2007) Advances in lafora progressive myoclonus epilepsy. Curr. Neurol. Neurosci. Rep., 7, 428-433.
5. Ganesh, S., Puri, R., Singh, S., Mittal, S. and Dubey, D. (2006) Recent advances in the molecular basis of Lafora's progressive myoclonus epilepsy. J. Hum. Genet., 51,1-8.
6. Lafora, G. and Glueck, B. (1911) Beitrag zur Histopathologie der myoklonischen Epilepsie. Z. Ges. Neurol. Psychiatr., 6, 1-14.
7. Carpenter, S. and Karpati, G. (1981) Sweat gland duct cells in Lafora disease: diagnosis by skin biopsy. Neurology, 31, 1564-1568.
8. Chan, E.M., Omer, S., Ahmed, M., Bridges, L.R., Bennett, C., Scherer, S.W. and Minassian, B.A. (2004) Progressive myoclonus epilepsy with polyglucosans (Lafora disease): evidence for a third locus. Neurology, 63, 565-567.
9. Minassian, B.A., Lee, J.R., Herbrick, J.A., Huizenga, J., Soder, S., Mungall, A.J., Dunham, I., Gardner, R., Fong, C.Y., Carpenter, S. et al. (1998) Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat. Genet., 20, 171-174.
10. Chan, E.M., Young, E.J., Ianzano, L., Munteanu, I., Zhao, X., Christopoulos, C.C., Avanzini, G., Elia, M., Ackerley, C.A., Jovic, N.J. et al. (2003) Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat. Genet., 35, 125-127.
11. Ganesh, S., Agarwala, K.L., Ueda, K., Akagi, T., Shoda, K., Usui, T., Hashikawa, T., Osada, H., Delgado-Escueta, A.V. and Yamakawa, K. (2000) Laforin, defective in the progressive myoclonus epilepsy of Lafora type, is a dual-specificity phosphatase associated with polyribosomes. Hum. Mol. Genet., 9, 2251-2261.
12. Gentry, M.S., Worby, C.A. and Dixon, J.E. (2005) Insights into Lafora disease: malin is an E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. Proc. Natl Acad. Sci. USA, 102, 8501-8506.
13. Singh, S., Sethi, I., Francheschetti, S., Riggio, C., Avanzini, G., Yamakawa, K., Delgado-Escueta, A.V. and Ganesh, S. (2006) Novel NHLRC1 mutations and genotype-phenotype correlations in patients with Lafora's progressive myoclonic epilepsy. J. Med. Genet., 43, e48.
14. Lohi, H., Ianzano, L., Zhao, X.C., Chan, E.M., Turnbull, J., Scherer, S.W., Ackerley, C.A. and Minassian, B.A. (2005) Novel glycogen synthase kinase 3 and ubiquitination pathways in progressive myoclonus epilepsy. Hum. Mol. Genet., 14, 2727-2736.
15. Solaz-Fuster, M.C., Gimeno-Alcaniz, J.V., Ros, S., Fernandez-Sanchez, M.E., Garcia-Fojeda, B., Criado Garcia, O., Vilchez, D., Dominguez, J., Garcia-Rocha, M., Sanchez-Piris, M. et al. (2008) Regulation of glycogen synthesis by the laforin-malin complex is modulated by the AMP-activated protein kinase pathway. Hum. Mol. Genet., 17, 667-678.
16. Cheng, A., Zhang, M., Gentry, M.S., Worby, C.A., Dixon, J.E. and Saltiel, A.R. (2007) A role for AGL ubiquitination in the glycogen storage disorders of Lafora and Cori's disease. Genes Dev., 21, 2399-2409.
17. Vernia, S., Solaz-Fuster, M.C., Gimeno-Alcaniz, J.V., Rubio, T., Garcia-Haro, L., Foretz, M., de Cordoba, S.R. and Sanz, P. (2009) AMP-activated protein kinase phosphorylates R5/PTG, the glycogen targeting subunit of the R5/PTG-protein phosphatase 1 holoenzyme, and accelerates its down-regulation by the laforin-malin complex. J. Biol. Chem., 284, 8247-8255.
18. Worby, C.A., Gentry, M.S. and Dixon, J.E. (2008) Malin decreases glycogen accumulation by promoting the degradation of protein targeting to glycogen (PTG). J. Biol. Chem., 283, 4069-4076.
19. Vilchez, D., Ros, S., Cifuentes, D., Pujadas, L., Valles, J., Garcia-Fojeda, B., Criado-Garcia, O., Fernandez-Sanchez, E., Medrano-Fernandez, I., Dominguez, J. et al. (2007) Mechanism suppressing glycogen synthesis in neurons and its demise in progressive myoclonus epilepsy. Nat. Neurosci., 10, 1407-1413.
20. Ganesh, S., Delgado-Escueta, A.V., Sakamoto, T., Avila, M.R., Machado-Salas, J., Hoshii, Y., Akagi, T., Gomi, H., Suzuki, T., Amano, K. et al. (2002) Targeted disruption of the Epm2a gene causes formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy and impaired behavioral response in mice. Hum. Mol. Genet., 11, 1251-1262.
21. Chan, E.M., Ackerley, C.A., Lohi, H., Ianzano, L., Cortez, M.A., Shannon, P., Scherer, S.W. and Minassian, B.A. (2004) Laforin preferentially binds the neurotoxic starch-like polyglucosans, which form in its absence in progressive myoclonus epilepsy. Hum. Mol. Genet., 13, 1117-1129.
22. Wang, Y., Liu, Y., Wu, C., Zhang, H., Zheng, X., Zheng, Z., Geiger, T.L., Nuovo, G.J., Liu, Y. and Zheng, P. (2006) Epm2a suppresses tumor growth in an immunocompromised host by inhibiting Wnt signaling. Cancer Cell, 10, 179-190.
23. Garyali, P., Siwach, P., Singh, P.K., Puri, R., Mittal, S., Sengupta, S., Parihar, R. and Ganesh, S. (2009) The malin-laforin complex suppresses the cellular toxicity of misfolded proteins by promoting their degradation through the ubiquitin-proteasome system. Hum. Mol. Genet., 18, 688-700.
24. Yokoi, S., Austin, J., Witmer, F. and Sakai, M. (1968) Studies in myoclonus epilepsy (Lafora body form). I. Isolation and preliminary characterization of Lafora bodies in two cases. Arch. Neurol., 19, 15-33.
25. Sakai, M., Austin, J., Witmer, F. and Trueb, L. (1970) Studies in myoclonus epilepsy (Lafora body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in corpora amylacea. Neurology, 20, 160-176.
26. Tagliabracci, V.S., Girard, J.M., Segvich, D., Meyer, C., Turnbull, J., Zhao, X., Minassian, B.A., Depaoli-Roach, A.A. and Roach, P.J. (2008) Abnormal metabolism of glycogen phosphate as a cause for Lafora disease. J. Biol. Chem., 283, 33816-33825.
27. Sinha, S., Satishchandra, P., Gayathri, N., Yasha, T.C. and Shankar, S.K. (2007) Progressive myoclonic epilepsy: a clinical, electrophysiological and pathological study from South India. J. Neurol. Sci., 252, 16-23.
28. Glickman, M.H. and Ciechanover, A. (2002) The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol. Rev., 82, 373-428.
29. Singh, S., Satishchandra, P., Shankar, S.K. and Ganesh, S. (2008) Lafora disease in the Indian population: EPM2A and NHLRC1 gene mutations and their impact on subcellular localization of laforin and malin. Hum. Mutat., 29, E1-E12.
30. Liu, Y., Wang, Y., Wu, C., Liu, Y. and Zheng, P. (2009) Deletions and missense mutations of EPM2A exacerbate unfolded protein response and apoptosis of neuronal cells induced by endoplasm reticulum stress. Hum. Mol. Genet., 18, 2622-2631.
31. Rao, S.N., Sharma, J., Maity, R. and Jana, N.R. (2009) Co-chaperone CHIP stabilizes aggregate prone malin, an ubiquitin ligase mutated in Lafora disease. J. Biol. Chem., 16, 753-762.
32. Mittal, S., Dubey, D., Yamakawa, K. and Ganesh, S. (2007) Lafora disease proteins malin and laforin are recruited to aggresomes in response to proteasomal impairment. Hum. Mol. Genet., 16, 753-762.
33. Jana, N.R., Dikshit, P., Goswami, A. and Nukina, N. (2004) Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem., 279, 11680-11685.
34. Drexler, H.C. (1997) Activation of the cell death program by inhibition of proteasome function. Proc. Natl Acad. Sci. USA, 94, 855-860.
35. Li, X., Li, H. and Li, X.J. (2008) Intracellular degradation of misfolded proteins in polyglutamine neurodegenerative diseases. Brain Res. Rev., 59, 245-252.
36. Bence, N.F., Sampat, R.M. and Kopito, R.R. (2001) Impairment of the ubiquitin-proteasome system by protein aggregation. Science, 292, 1552-1555.
37. Rubinsztein, D.C. (2006) The roles of intracellular protein-degradation pathways in neurodegeneration. Nature, 443, 780-786.
38. Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M.J., Jonnalagada, S., Chernova, T. et al. (1998) The ubiquitin pathway in Parkinson's disease. Nature, 395, 451-452.
39. Vernia, S., Rubio, T., Heredia, M., Rodriguez de Cordoba, S. and Sanz, P. (2009) Increased endoplasmic reticulum stress and decreased proteasomal function in lafora disease models lacking the phosphatase laforin. PLoS ONE, 4, e5907.
40. Lansbury, P.T. and Lashuel, H.A. (2006) A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature, 443, 774-779.
41. Muchowski, P.J. and Wacker, J.L. (2005) Modulation of neurodegeneration by molecular chaperones. Nat. Rev. Neurosci., 6,11-22.
42. Esser, C., Alberti, S. and Hohfeld, J. (2004) Cooperation of molecular chaperones with the ubiquitin/proteasome system. Biochim. Biophys. Acta, 1695, 171-188.
43. Bercovich, B., Stancovski, I., Mayer, A., Blumenfeld, N., Laszlo, A., Schwartz, A.L. and Ciechanover, A. (1997) Ubiquitin-dependent degradation of certain protein substrates in vitro requires the molecular chaperone Hsc70. J. Biol. Chem., 272, 9002-9010.
44. Bukau, B., Weissman, J. and Horwich, A. (2006) Molecular chaperones and protein quality control. Cell, 125, 443-451.
45. McClellan, A.J., Tam, S., Kaganovich, D. and Frydman, J. (2005) Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol., 7, 736-741.
46. Jana, N.R., Tanaka, M., Wang, G. and Nukina, N. (2000) Polyglutamine length-dependent interaction of Hsp40 and Hsp70 family chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cellular toxicity. Hum. Mol. Genet., 9, 2009-2018.
47. Mishra, A., Dikshit, P., Purkayastha, S., Sharma, J., Nukina, N. and Jana, N.R. (2008) E6-AP promotes misfolded polyglutamine proteins for proteasomal degradation and suppresses polyglutamine protein aggregation and toxicity. J. Biol. Chem., 283, 7648-7656.
48. Dikshit, P., Chatterjee, M., Goswami, A., Mishra, A. and Jana, N.R. (2006) Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem., 281, 29228-29235.